JP6346269B2 - ナルトレキソンを用いたがんの処置 - Google Patents

ナルトレキソンを用いたがんの処置 Download PDF

Info

Publication number
JP6346269B2
JP6346269B2 JP2016512422A JP2016512422A JP6346269B2 JP 6346269 B2 JP6346269 B2 JP 6346269B2 JP 2016512422 A JP2016512422 A JP 2016512422A JP 2016512422 A JP2016512422 A JP 2016512422A JP 6346269 B2 JP6346269 B2 JP 6346269B2
Authority
JP
Japan
Prior art keywords
tlr9
cancer
pharmaceutical composition
subject
naltrexone
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2016512422A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016524602A (ja
JP2016524602A5 (enExample
Inventor
ダルグリッシュ，アンガス
アレン，レイチェル
Original Assignee
キャンサー ワクチン インスティテュート
キャンサー ワクチン インスティテュート
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by キャンサー ワクチン インスティテュート, キャンサー ワクチン インスティテュート filed Critical キャンサー ワクチン インスティテュート
Publication of JP2016524602A publication Critical patent/JP2016524602A/ja
Publication of JP2016524602A5 publication Critical patent/JP2016524602A5/ja
Application granted granted Critical
Publication of JP6346269B2 publication Critical patent/JP6346269B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
    • C07D489/06—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: with a hetero atom directly attached in position 14
    • C07D489/08—Oxygen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Emergency Medicine (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2016512422A 2013-05-10 2014-05-12 ナルトレキソンを用いたがんの処置 Active JP6346269B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1308440.5 2013-05-10
GB201308440A GB201308440D0 (en) 2013-05-10 2013-05-10 Therapeutic
PCT/GB2014/051439 WO2014181131A1 (en) 2013-05-10 2014-05-12 Treatment of cancer with naltrexone

Publications (3)

Publication Number Publication Date
JP2016524602A JP2016524602A (ja) 2016-08-18
JP2016524602A5 JP2016524602A5 (enExample) 2017-04-13
JP6346269B2 true JP6346269B2 (ja) 2018-06-20

Family

ID=48672126

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016512422A Active JP6346269B2 (ja) 2013-05-10 2014-05-12 ナルトレキソンを用いたがんの処置

Country Status (13)

Country Link
US (4) US9895438B2 (enExample)
EP (1) EP2994137B1 (enExample)
JP (1) JP6346269B2 (enExample)
KR (1) KR102162038B1 (enExample)
CN (1) CN105451740B (enExample)
AU (1) AU2014264445B2 (enExample)
BR (1) BR112015028269A2 (enExample)
CA (1) CA2912203C (enExample)
GB (1) GB201308440D0 (enExample)
IL (1) IL242533B (enExample)
MX (1) MX2015015582A (enExample)
RU (1) RU2686325C2 (enExample)
WO (1) WO2014181131A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201410216D0 (en) * 2014-06-09 2014-07-23 Cancer Vaccine Inst Therapeutic
GB201704911D0 (en) * 2017-03-28 2017-05-10 Ldn Pharma Ltd High dose combo I
CN111050801B (zh) * 2017-03-28 2023-03-28 Ldn制药有限公司 用于治疗癌症的增加bcl2-相关的细胞死亡激动剂表达的药剂
WO2019055597A1 (en) * 2017-09-13 2019-03-21 National Tuberous Sclerosis Association, Inc. Methods and compositions for the treatment of tsc
CA3113895A1 (en) * 2018-11-01 2020-05-07 Faron Pharmaceuticals Oy Tlr9 agonists for use in downregulating clever-1 expression on alternatively activated macrophages
WO2020178446A1 (en) * 2019-03-06 2020-09-10 LDN Pharma Limited Method of monitoring treatment
GB201903546D0 (en) * 2019-03-15 2019-05-01 Ldn Pharma Ltd Cancer treatment
AU2022211609A1 (en) * 2021-01-25 2023-07-27 LDN Pharma Limited Naltrexone compositions
CN114836529B (zh) * 2022-03-30 2023-05-30 唐颢 Ogfr基因或其编码的蛋白在心肌损伤辅助诊断及治疗中的应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4689332A (en) * 1984-04-09 1987-08-25 Research Corporation Growth regulation and related applications of opioid antagonists
GB8728294D0 (en) * 1987-12-03 1988-01-06 Reckitt & Colmann Prod Ltd Treatment compositions
US6136780A (en) * 1996-03-29 2000-10-24 The Penn State Research Foundation Control of cancer growth through the interaction of [Met5 ]-enkephalin and the zeta (ζ) receptor
EP0945133A1 (en) * 1998-03-26 1999-09-29 Lipha Combination for the treatment of alcohol and drug dependence containing an opioid antagonist and a NMDA receptor complex modulator
US6288074B1 (en) * 1998-11-17 2001-09-11 Bernard Bihari Method of treating lymphoproliferative syndrome
US6194382B1 (en) * 1999-03-03 2001-02-27 Albert Einstein College Of Medicine Of Yeshiva University Method and composition for treating irritable bowel syndrome using low doses of opioid receptor antagonists
US6384044B1 (en) * 1999-11-29 2002-05-07 Bernard Bihari Method of treating cancer of the prostate
CN103405431B (zh) * 2002-05-17 2016-04-13 台湾J药品有限公司 阿片和阿片样化合物及其用途
US8017622B2 (en) * 2003-05-16 2011-09-13 Jenken Biosciences, Inc. Opioid and opioid-like compounds and uses thereof
GB0509052D0 (en) 2005-05-04 2005-06-08 Aimsco Ltd Combination therapy
US20090191185A1 (en) * 2006-04-26 2009-07-30 The Uab Research Foundation Reducing Cancer Cell Invasion Using an Inhibitor of Toll Like Receptor Signaling
WO2011009015A1 (en) * 2009-07-16 2011-01-20 Mallinckrodt Inc. (+) - morphinans as antagonists of toll-like receptor 9 and therapeutic uses thereof
EP2593095B1 (en) 2010-07-16 2019-03-27 Mallinckrodt LLC (+)-morphinans as antagonists of toll-like receptor 9 and therapeutic uses thereof
GB201410216D0 (en) * 2014-06-09 2014-07-23 Cancer Vaccine Inst Therapeutic
GB201704909D0 (en) * 2017-03-28 2017-05-10 Ldn Pharma Ltd Cancer therapy
GB201704911D0 (en) * 2017-03-28 2017-05-10 Ldn Pharma Ltd High dose combo I

Also Published As

Publication number Publication date
CA2912203A1 (en) 2014-11-13
EP2994137A1 (en) 2016-03-16
GB201308440D0 (en) 2013-06-19
US20220040295A1 (en) 2022-02-10
BR112015028269A2 (pt) 2017-07-25
IL242533B (en) 2020-10-29
WO2014181131A1 (en) 2014-11-13
NZ714999A (en) 2021-05-28
AU2014264445A1 (en) 2016-01-07
KR20160032013A (ko) 2016-03-23
CN105451740A (zh) 2016-03-30
KR102162038B1 (ko) 2020-10-06
RU2686325C2 (ru) 2019-04-25
CA2912203C (en) 2021-08-17
JP2016524602A (ja) 2016-08-18
CN105451740B (zh) 2019-07-19
MX2015015582A (es) 2016-08-11
EP2994137B1 (en) 2022-12-14
US20160106832A1 (en) 2016-04-21
US20180207263A1 (en) 2018-07-26
AU2014264445B2 (en) 2019-08-15
RU2015152785A (ru) 2017-06-16
US9895438B2 (en) 2018-02-20
US20230390388A1 (en) 2023-12-07

Similar Documents

Publication Publication Date Title
JP6346269B2 (ja) ナルトレキソンを用いたがんの処置
Martinez et al. The role of chloroquine and hydroxychloroquine in immune regulation and diseases
Stolfi et al. Involvement of interleukin-21 in the regulation of colitis-associated colon cancer
JP6902040B2 (ja) 免疫チェックポイント阻害剤の効力を増強する方法
JP6620338B2 (ja) 低用量ナルトレキソンによるがん細胞の準備刺激
Zhang et al. Chloroquine (CQ) exerts anti-breast cancer through modulating microenvironment and inducing apoptosis
Salem et al. Acute inflammation induces immunomodulatory effects on myeloid cells associated with anti-tumor responses in a tumor mouse model
Calderon-Gonzalez et al. Gold glyconanoparticles coupled to listeriolysin O 91–99 peptide serve as adjuvant therapy against melanoma
Wang et al. Thalidomide suppresses breast cancer tumor growth by inhibiting tumor-associated macrophage accumulation in breast tumor-bearing mice
Das et al. TLR9 and MyD88 are crucial for the maturation and activation of dendritic cells by paromomycin–miltefosine combination therapy in visceral leishmaniasis
JP2023522979A (ja) ｉＮＫＴ細胞の活性化による老化細胞の排除
US20240408071A1 (en) Novel combination of serotonin receptor (5-htr2b) antagonist and an immunomodulator and chemotherapeutic drugs for inhibition of cancer
WO2024006821A2 (en) Methods of treating a tumor
EP3311840B1 (en) Treatment-resistance reducing agent for treatment-resistant cancer
NZ714999B2 (en) Treatment of cancer with naltrexone
US20250381248A1 (en) Methods of treating a tumor
US20220347180A1 (en) Enhancing cancer therapy treatment with bh3 mimetics
Sandhu Investigating the Anti-Tumoral Mechanism of an Immature Dendritic Cell Targeting Vaccine in Combination with 5-Aza-2’deoxycytidine and IFNα in the B16F10 Murine Melanoma Model
Robinson et al. Paclitaxel inhibits killing by murine cytotoxic T lymphocytes in vivo but not in vitro
Janji et al. Emerging role of hypoxia-induced autophagy in cancer immunotherapy
WO2025228595A1 (en) Use of compound ia in the treatment of cancers including combination therapy with atezolizumab.
Di Grazia et al. Rafoxanide Induces Immunogenic Death of Colorectal Cancer Cells.
KR20140102811A (ko) 이미퀴모드를 포함하는 항암 치료 보조용 약학 조성물
TW201909894A (zh) 包含血管破壞劑及免疫查核點抑制劑之用於預防或治療癌症的組合物
EP3497235A1 (en) Tirc7 based diagnostic and therapy of solid cancer

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160624

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170310

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170310

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20171107

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180206

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180220

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180411

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20180424

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20180524

R150 Certificate of patent or registration of utility model

Ref document number: 6346269

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250